The prodromal microbiome.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

13 citing papers in PubMed.

1. Temporin-1CEa and its Analog LK2(6)A(L) Confer Neuroprotective Effects in Parkinson's Disease Model by Attenuating Neuroinflammation Via the NF-κB and MAPK Signaling Pathways.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2025
   Article
2. The gut-brain axis in early Parkinson's disease: from prodrome to prevention.Journal of neurology · 2025
   Review
3. Gut microbiota-associated taurine metabolism dysregulation in a mouse model of Parkinson's disease.mSphere · 2023
   Article
4. The Gut-Brain Axis: Two Ways Signaling in Parkinson's Disease.Cellular and molecular neurobiology · 2022
   Review
5. Functions of Intracellular Alpha-Synuclein in Microglia: Implications for Parkinson's Disease Risk.Frontiers in cellular neuroscience · 2021
   Review
6. [The role of the gut microbiome in idiopathic Parkinson's disease].Der Nervenarzt · 2020
   Review
7. Parkinson's disease and the gastrointestinal microbiome.Journal of neurology · 2020
   Review
8. Minireview on the Relations between Gut Microflora and Parkinson's Disease: Further Biochemical (Oxidative Stress), Inflammatory, and Neurological Particularities.Oxidative medicine and cellular longevity · 2020
   Review
9. Gut Vibes in Parkinson's Disease: The Microbiota-Gut-Brain Axis.Movement disorders clinical practice · 2019
   Review
10. Triggers, Facilitators, and Aggravators: Redefining Parkinson's Disease Pathogenesis.Trends in neurosciences · 2019
    Review
11. Diagnostic biomarkers for Parkinson's disease at a glance: where are we?Journal of neural transmission (Vienna, Austria : 1996) · 2018
    Review
12. Changes of Colonic Bacterial Composition in Parkinson's Disease and Other Neurodegenerative Diseases.Nutrients · 2018
    Review
13. The Microbiome-Mitochondria Dance in Prodromal Parkinson's Disease.Frontiers in physiology · 2018
    Review

Corrections and comments

• Comment on
  The nasal and gut microbiome in Parkinson's disease and idiopathic rapid eye movement sleep behavior disorder.2018

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as